
    
      Participation in the study is planned to last up to 18 weeks. A single-blind placebo run-in
      period of 4 to 6 weeks after which participants will be randomized into a double-blind
      treatment period of 8 weeks and a washout and follow-up period ending with an end-of-study
      visit approximately 12 weeks after randomization.
    
  